{"id":67727,"date":"2025-09-30T10:06:21","date_gmt":"2025-09-30T10:06:21","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=67727"},"modified":"2025-10-04T06:33:57","modified_gmt":"2025-10-04T06:33:57","slug":"antiarrhythmic-effect-of-1-3-bromophenyl-67-methylenedioxy-1234-tetrahydroisoquinoline-hydrochloride","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol18no3\/antiarrhythmic-effect-of-1-3-bromophenyl-67-methylenedioxy-1234-tetrahydroisoquinoline-hydrochloride\/","title":{"rendered":"Antiarrhythmic Effect of 1-(3\u02ca-Bromophenyl)-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline Hydrochloride"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

Cardiovascular diseases remain one of the primary causes of illness and death across numerous countries worldwide. Cardiac arrhythmia, the most common cardiovascular disease, is one of the most important risk factors for sudden death.1<\/sup> The pathogenesis of cardiac arrhythmia is based on functional damage to the heart, leading to a violation of the most important parameters of the myocardium: contraction frequency and contractile activity. The effect of most antiarrhythmic drugs is based on the correction of these parameters, but many of them do not fully meet the requirements of clinical practice and have a number of additional side effects. From this point of view, the creation and production of a new generation of safe and highly effective antiarrhythmic drugs is one of the urgent problems of modern pharmacology and cardiology.<\/p>\n

The pathogenesis of cardiac arrhythmias is based on a violation of the electrophysiological properties of cardiomyocytes, which are responsible for excitability, automatism, and the generation of action potentials (AP).2,3<\/sup> In this regard, the modern concept of preventing and treating cardiac arrhythmias places a leading role in the development of new approaches to correcting these disorders, including the creation of new generation antiarrhythmic drugs.<\/p>\n

The normal rhythmic activity of the heart depends on the synchrony in the function of ion channels, and serious changes in this system are directly manifested in the form of arrhythmia.4,5<\/sup> The mutation results in a phenotype of dysfunction of cardiomyocyte Na+<\/sup> and K+<\/sup> channels, leading to a number of arrhythmias.6<\/sup>-8 <\/sup>LQT syndrome, SQT syndrome, Brugada syndrome, catecholaminergic polymorphic tachycardia syndromes are associated with mutations in the genome of cardiomyocyte ion channels.9,10<\/sup> Also, a number of arrhythmias, such as Andersen and Timothy syndromes, are not caused by a single mutation, but by multisystem disorders. In the cardiomyocyte, the Na+<\/sup> channel is activated in AP 0-phase, its function disorders lead to tachyarrhythmia.11<\/sup><\/p>\n

At present, antiarrhythmic drugs are categorized based on their specific characteristics. The E. Vaughan-Williams classification system categorizes these drugs into four primary classes: Class I \u2013 sodium channel blockers; Class II \u2013 beta-adrenoceptor blockers; Class III \u2013 potassium channel blockers; and Class IV \u2013 calcium channel blockers.12<\/sup><\/p>\n

Class I includes Na+<\/sup> channel blockers, which are characterized by slowing of the rate of AP depolarization, excitability, and signal transmission, and changes in the QT interval on the ECG. LQTS syndrome, associated with mutations in the genome of Na+<\/sup> and K+<\/sup> channels, occurs in both acquired and inherited forms, and in the acquired form, antihistamines and antiarrhythmic pharmacological drugs are used.13,14<\/sup><\/p>\n

Antiarrhythmic drugs used in the treatment of cardiac arrhythmias are based on inhibiting the function of Na+<\/sup>, Ca2+<\/sup>, and K+<\/sup> channels and adrenoreceptors.15<\/sup> Alkaloids exhibit a broad spectrum of pharmacological effects, and many have found applications in both traditional and modern medicine, as well as serving as key starting materials for drug development. Among them, the isoquinoline, indole, and purine alkaloids are currently the most extensively researched in pharmacological studies.16-18 <\/sup>The pharmacological properties of berberine include its antiarrhythmic activity and its potential application in the management of hypertension.19<\/sup> Overall, medications primarily composed of isoquinoline alkaloids are currently being effectively utilized in the treatment of conditions such as pain, atherosclerosis, hypertension, myocardial infarction, cardiomyopathy, heart failure, and various types of arrhythmias.20-23<\/sup> In this context, isoquinoline alkaloids hold significant potential as a valuable source for creating new antiarrhythmic drugs, thanks to their structural diversity and wide range of pharmacological actions. \u00a0Investigating the biological activities of these alkaloids will lay the groundwork for discovering promising candidates to develop next-generation antiarrhythmic drugs aimed at treating and preventing cardiac arrhythmias.<\/p>\n

Materials and <\/strong>M<\/strong>ethods<\/strong><\/p>\n

The experiments were conducted at the Laboratory of Cellular Biophysics, Institute of Biophysics and Biochemistry, National University of Uzbekistan. The studies used white, non-purebred rats weighing between 200 and 250 grams. The international Declaration of Helsinki and the guidelines developed by the Council for International Organizations of Medical Sciences (CIOMS; The Council for International Organizations of Medical Sciences<\/em>) (1985) were followed when working with experimental animals.<\/p>\n

The mechanography method was used to study the mechanism of action of biologically active substances on the functional role of the myocardium of experimental animals In vitro.<\/em> Experimental animals are a convenient object of research for elucidating the mechanisms of antiarrhythmic action of pharmacological agents In vitro<\/em>, under normal physiological and pathological conditions.<\/p>\n

The experimental animals were anesthetized using diethyl ether and euthanized by cervical dislocation. The thoracic cavity was then surgically opened to remove the heart. A papillary muscle sample (diameter 0.4-1.3 mm; length 2.5-3.8 mm) was isolated and placed in a Petri dish containing Krebs-Henseleit physiological solution. The preparation was subsequently transferred to a specialized horizontal experimental bath (type 813, volume 5 ml) (Hugo Sachs Electronic, Germany) designed for studying the muscle\u2019s isometric contraction activity. The papillary muscle preparation was incubated in a Krebs-Henseleit physiological solution, the temperature of the solution was maintained constant (t=+36\u00b10.5\u00b0C) using a thermostat (LOIP LT-108a, Russia), and aerated with carbogen (O2-95%, CO2-5%). Circulation of physiological solution (3-5 ml\/minute) was ensured by LKB Bromma (Sweden) peristaltic pumps. The papillary muscle preparation was connected to an F30 mechanotron (Model D-79232; HSE, Germany), and the cardiac muscle preparation was stimulated with an electrical impulse ~20% above the threshold level at a frequency of 1 Hz (5-10 ms; 3 V) using an electrostimulator \u0421 type 224 (HSE, Germany) with two platinum (Pt) wire electrodes. The isometric mechanical activity of the papillary muscle was recorded on a computer in a special digital format using an analog-to-digital converter LabPro Logger Lite 1.2 (Vernier Software & Technology, Beaverton, USA) through an amplifier (TAM-A, HSE GmbH, Germany). The research used Krebs-Henseleit physiological solution with the following composition (mM): NaCl-118; KCl-4.7; CaCl2<\/sub>-2.5; MgSO4<\/sub>-1.2; KH2<\/sub>PO4<\/sub>-1.1; glucose-5.5; NaHCO3<\/sub>-25 (pH=7.4) [24].<\/p>\n

Aconitine Arrhythmia Model<\/strong><\/p>\n

The experiments used a model of arrhythmia induced by aconitine. It is known that aconitine increases the activity of Na+<\/sup> channels in cardiomyocytes, leading to an increase in the concentration of Na+<\/sup> in the cytosol, and as a result of the entry of Ca2+<\/sup> ions through the Na+<\/sup>\/Ca2+<\/sup>– exchange system, the concentration of Ca2+<\/sup> increases and arrhythmia occurs. Arrhythmia occurs 7-10 minutes after adding aconitine (1 \u03bcM) to the incubation medium.25,26<\/sup> The antiarrhythmic effect of the isoquinoline alkaloid F-25 was evaluated in this experimental arrhythmia model.<\/p>\n

Statistics<\/strong><\/p>\n

In this study, all results are expressed as mean \u00b1 SD. Analysis of variance was used to compare control values between groups. The statistical reliability of the values between the experimental results and the control group was calculated based on the Student’s t-test and was considered statistically reliable at values of \u0440<0.05, \u0440<0.01. The statistical analysis was conducted with Origin Pro version 9.1. (OriginLab Co., U.S.A).<\/p>\n

Method for the synthesis of 1-(3\u2032-bromophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (F-25), C\u2081\u2087H\u2081\u2088O\u2082NBr\u00b7HCl<\/strong><\/p>\n

The compound 1-(3\u2032-bromophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (F-25) was synthesized using a previously described method. 27<\/sup><\/p>\n\n\n\n
\"\"<\/td>\nScheme 1: Synthesis of 1-(3\u2032-bromophenyl)-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (F-25).<\/strong><\/p>\n

Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The compound 1-(3\u2032-bromophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (F-25) was obtained by a new method, in contrast to a mixture of 5.0 g (0.027 mol) of 3,4-dimethoxyphenylethylamine (1) and 5.11 g (0.027 mol) of 3-bromobenzaldehyde (2) in 10 mL of trifluoroacetic acid was refluxed for 4 hours. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was cooled and basified with 5% aqueous sodium hydroxide solution to pH 9\u201310. The product was then exhaustively extracted with chloroform. After evaporation of the chloroform, the crude product was dissolved in acetone and acidified with concentrated HCl to pH 5\u20136. The resulting precipitate of the hydrochloride was filtered and washed three times with acetone. Yield: 9.22 g (96%), m.p. 248\u2013251\u202f\u00b0C (from acetone), Rf 0.82 (chloroform:methanol = 12:1).<\/p>\n

IR spectrum (<\/strong>KBr<\/strong>, \u03bd<\/strong>max<\/sub><\/strong>, <\/sub><\/strong>cm-1<\/sup>):<\/strong> 3244, 3235, 2994, 2960, 2922, 2892, 2826, 2722, 1610, 1590, 1508, 1456, 1331, 1253, 1214, 1177, 1114, 1043, 1018, 969, 852, 818;<\/p>\n

NMR 1<\/sup>\u041d (600 <\/strong>MHz<\/strong>, \u0421<\/strong>D<\/strong>\u0421<\/strong>l<\/strong>3<\/sub><\/strong>, <\/strong> \u00a0<\/strong>m<\/strong>.<\/strong>d<\/strong>., J\/<\/strong>Hz<\/strong>):<\/strong> 1.85 (1H, \u0441, NH), 2.72 (1\u041d, \u0434\u0442, J=4.7, 15.9, Ha<\/sub>-4), 2.90 (1\u041d, \u0434\u0434\u0434, J= 5.3, 8.2, 15.9,\u00a0 Hb<\/sub>-4), 3.01 (1\u041d, \u0434\u0434\u0434, J= 4.7, 8.1, 12.2, Ha<\/sub>-3), 3.16 (1H, \u0434\u0442, J= 5.3, 12.2, Hb<\/sub>-3), 3.64 (3\u041d, \u0441, 7-\u041e\u0421\u041d3<\/sub>), 3.86 (3\u041d, \u0441, 6-\u041e\u0421\u041d3<\/sub>), 4.99 (1\u041d, \u0441, \u041d-1), 6.20 (1\u041d, \u0441, \u041d-8), 6.62 (1\u041d, \u0441, \u041d-5), 7.11-7.17 (2H, \u043c, Ar-\u041d), 7.37-7.40 (2\u041d, \u043c, Ar-\u041d);<\/p>\n

NMR 13<\/sup>C (150 <\/strong>MHz<\/strong>, \u0421<\/strong>D<\/strong>\u0421<\/strong>l<\/strong>3<\/sub><\/strong>, <\/strong> \u00a0<\/strong>m<\/strong>.<\/strong>d<\/strong>.):<\/strong> 29.29 (\u0421-4), 41.77 (\u0421-3), 55.94 (6-\u041e\u0421\u041d3<\/sub>), 56.02 (7-\u041e\u0421\u041d3<\/sub>), 61.02 (\u0421-1), 110.90 (\u0421-8), 111.63 (\u0421-5), 122.64 (\u0421-3\u2032), 127.69 (\u0421-6\u2032), 127.82 (\u0421-4\u0430), 129.04 (\u0421-8a),\u00a0 130.03 (\u0421-5\u2032), 130.59 (C-4\u2032), 132.00 (\u0421-2\u2032), 147.24 (\u0421-1\u2032), 147.43 (\u0421-7), 147.90 (\u0421-6).<\/p>\n

Results <\/strong><\/p>\n

Isoquinoline alkaloids, which are heterocyclic chemical compounds, exhibit a broad range of physiological effects.28-30<\/sup> Specifically, isoquinoline alkaloids have been shown to possess antiarrhythmic and inotropic properties in cardiovascular diseases.31,32<\/sup> Therefore, the mechanisms of antiarrhythmic action of the isoquinoline alkaloid F-25 have been clarified. The experiments investigated the dose-dependent impact of the alkaloid F-25 on the contractile function of rat cardiac papillary muscles. The alkaloid demonstrated a negative inotropic effect on the contractile activity of rat heart papillary muscle across all tested concentrations. Accordingly, when examining the effects of the alkaloid F-25 at concentrations ranging from 10 \u03bcM to 100 \u03bcM, the greatest effect was observed at 100 \u03bcM, where it reduced the muscle contraction force by 87.6\u00b14.2% compared to the control. (Figures 1(A) and 1(B)). The half-maximal effective concentration (IC50<\/sub><\/em>) of the alkaloid F-25 was 34.4 \u03bcM, respectively.<\/p>\n\n\n\n
\"\"<\/td>\nFigure 1: (A) Dose-dependent negative inotropic effect of the F-25 alkaloid\u2019s effect on the contraction function of rat cardiac papillary muscles (original record<\/em>). (B) Dose-dependent inotropic effect of the alkaloid F-25.<\/strong><\/p>\n

Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

During membrane depolarization of cardiac muscle cells, the entry of Na+<\/sup> ions into the cardiomyocyte activates the sarcolemmal L-type \u0421\u04302+<\/sup> channel, and \u0421\u04302+<\/sup> ions entering the cytosol stimulate the release of \u0421\u04302+<\/sup> ions from the SR.33,34<\/sup> As the amount of [Ca2+<\/sup>]i<\/sub> in the cytosol increases, Ca2+<\/sup> ions bind to the troponin C protein in the myofilament, causing contraction.35,36<\/sup> Blocking Na+<\/sup> channels reduces the intracellular concentration of Na+<\/sup> ions in cardiomyocytes, which leads to a decrease in [Ca2+<\/sup>]i <\/sub>and a subsequent reduction in the strength of cardiac muscle contraction.37-39<\/sup><\/p>\n

The negative inotropic effect of the alkaloid F-25 on the contractile function of rat cardiac papillary muscle may result from the inhibition of Na+<\/sup> channels in cardiomyocytes.Therefore, to assess the role of voltage-gated Na+<\/sup> channels in providing the negative inotropic effect of the alkaloid F-25, experiments were conducted using lidocaine, a specific blocker of these channels.<\/p>\n\n\n\n
\"\"<\/td>\nFigure 2: Lidocaine\u2019s dose-related impact on papillary muscle contraction. The ordinate axis shows the amplitude value of the contraction force represented as a percentage (%) of the maximum,<\/strong><\/p>\n

Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

In initial control experiments, the dose-dependent effect of lidocaine (ranging from 5 to 30 \u03bcM) on papillary muscle contraction activity was examined at a stimulation frequency of 1 Hz. It was observed that lidocaine reduced the amplitude of papillary muscle contraction force by 89.6\u00b14.2% at a concentration of 30 \u00b5M compared to the control. It was found that the concentration of lidocaine that inhibits muscle contraction by 50% (IC50<\/sub><\/em>) was 15.4 \u03bcM (Figure 2).<\/p>\n

In cardiac muscle cells, lidocaine blocks the Na+<\/sup> channel, resulting in a decrease in [Na+<\/sup>]i<\/sub> in the cytosol. Lidocaine causes a decrease in the force of papillary muscle contraction under lidocaine influence, which increases the release of Ca2+<\/sup> through the Na+<\/sup>\/Ca2+<\/sup> exchange system and is accompanied by a decrease in the amount of [Ca2+<\/sup>]i<\/sub> in the cytosol.<\/p>\n

In subsequent experiments, when the effect of alkaloid F-25 (100 \u03bcM) was tested in the presence of lidocaine (IC50<\/sub><\/em>=15.4 \u03bcM) in incubation conditions, the amplitude of papillary muscle contraction force was 32.8\u00b13.9%, respectively (Figures 3(A) and 3(B)). The negative inotropic effect of alkaloid F-25 was found to decrease in conditions involving lidocaine. Analysis of the experimental results indicates that this alkaloid blocks Na+<\/sup> channels located in the membrane of cardiomyocytes, resulting in a decrease in the amount of [Na+<\/sup>]i<\/sub> in the cytosol and, as a result, a decrease in the entry of Ca2+<\/sup> ions into the cell through the Na+<\/sup>\/Ca2+<\/sup> exchange system. In addition, the negative inotropic effect of the alkaloid F-25 indicates that other ion transport systems are also involved in the alkaloid’s negative inotropic effect.<\/p>\n\n\n\n
\"\"<\/td>\nFigure 3: (A) Influence of alkaloid F-25 on the contractile force of rat cardiac papillary muscle in the presence of lidocaine (original <\/em>record<\/em>). (B) The inotropic action of alkaloid F-25 on the contraction strength of papillary muscle in the presence of lidocaine.<\/strong><\/p>\n

Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

In cardiomyocytes, the entry of Na+<\/sup> ions into the cytosol is ensured not only by Na+<\/sup> channels but also by Na+<\/sup>\/Ca2+<\/sup> exchange.40<\/sup> Na+<\/sup>\/Ca2+<\/sup> exchange is recognized as a key factor in regulating Ca2+<\/sup> ion dynamics within cardiomyocytes and pacemaker function, and it can also play a role in the development of arrhythmias in certain situations.41,42<\/sup> As a result of the increase in the concentration of [Ca2+<\/sup>]i<\/sub> in the cardiomyocyte cytosol, the outflow of Ca2+<\/sup> ions from the SR increases, and the influx of Na+<\/sup> ions through the Na+<\/sup>\/Ca2+<\/sup> exchanger increases, resulting in early afterdepolarization in the plateau phase of the AP and arrhythmia.43<\/sup><\/p>\n

Based on the above, the F-25 alkaloid may exert a negative inotropic effect by modulating the Na+<\/sup>\/Ca2+<\/sup> exchange function. To verify this hypothesis, further experiments were conducted to assess the impact of the F-25 alkaloid on Na+<\/sup>\/Ca2+ <\/sup>exchange in the presence of its non-specific blocker, NiCl2<\/sub>. In the presence of 10 mM NiCl2<\/sub> in the incubation medium, the negative inotropic effect of the F-25 alkaloid (100 \u03bcM) on the papillary muscle contraction activity was 42.3\u00b14.2% (Figures 4(A) and 4(B)). These data indicate that Na+<\/sup>\/Ca2+<\/sup> exchange is partially involved in the negative inotropic effect of the alkaloid F-25.<\/p>\n\n\n\n
\"\"<\/td>\nFigure 4: (A) Influence of the alkaloid F-25 on the contractile strength of rat cardiac papillary muscle in the presence of NiCl\u2082 (original record<\/em>). (B) The inotropic effect of alkaloid F-25 on papillary muscle contraction force in the presence of NiCl\u2082.<\/strong><\/p>\n

Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Class I antiarrhythmic drugs consist of pharmacological agents that are crucial for restoring the normal physiological function of Na\u207a channels in cardiomyocytes and correcting their dysfunction.44<\/sup> In the next experiments, to evaluate the antiarrhythmic effect of the alkaloid F-25, its antiarrhythmic effect was tested on an experimental arrhythmia model induced by aconitine. In this case, exposure to 1 \u03bcM aconitine led to an increase in the force of papillary muscle contraction and, after 7-10 minutes, to the occurrence of spontaneous contraction, that is, arrhythmia.<\/p>\n\n\n\n
\"\"<\/td>\nFigure 5: Antiarrhythmic effect of the alkaloid F-25 on aconitine-induced arrhythmia.<\/strong><\/p>\n

Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The arrhythmia caused by aconitine results in an elevated concentration of Na\u207a ions, which subsequently enhances the Na\u207a\/Ca\u00b2\u207a exchange process, increasing the swapping of Na\u207a ions for Ca\u00b2\u207a ions. This type of activation of the Na+<\/sup>\/Ca2+<\/sup> exchange in cardiomyocytes enhances the entry of Ca2+<\/sup> into the cytosol and leads to spontaneous release of Ca2+<\/sup> from the SR and cardiac rhythm disturbances. Upon investigating the impact of the alkaloid F-25 on aconitine-induced arrhythmia, we observed a reduction in heart rate from 246\u00b112 beats per minute to 65\u00b16 beats per minute (Figure 5).<\/p>\n

Discussion<\/strong><\/p>\n

Isoquinoline alkaloids have a very broad pharmacological activity, and one of their most important properties is their antiarrhythmic effect.45<\/sup> In particular, pharmacological studies conducted on berberine show that it exhibits vasodilating and antiarrhythmic effects.46<\/sup><\/p>\n

Class I antiarrhythmic drugs are pharmacological agents that play a key role in restoring the normal physiological function of Na\u207a channels in cardiomyocytes by correcting their abnormal activity.47<\/sup> To evaluate the antiarrhythmic effect of these alkaloids in the experiments, the antiarrhythmic effect on the experimental arrhythmia model induced by aconitine was examined. Aconitine-induced arrhythmia results in elevated intracellular Na+ <\/sup>levels, which subsequently enhances the exchange of\u00a0 Na+<\/sup> for Ca2+<\/sup> via the Na+<\/sup>\/Ca2+<\/sup> exchanger.48<\/sup> This mode of Na\u207a\/Ca\u00b2\u207a exchanger activation in cardiomyocytes increases Ca\u00b2\u207a influx into the cytosol, triggering spontaneous Ca\u00b2\u207a release from the sarcoplasmic reticulum and resulting in cardiac rhythm disturbances. The alkaloid F-25 effectively eliminates disturbances in the contractile activity of the heart muscle that occur as a result of arrhythmias caused by Aconitine.<\/p>\n

Conclusion<\/strong><\/p>\n

In cardiomyocytes, the Na+<\/sup> channel is a substrate for the action of class I antiarrhythmic drugs.49,50<\/sup> Open and inactive channels are more prone to blocking than quiescent channels. Binding to antiarrhythmic drugs occurs mainly during the action potential. And this block extends to the time interval between action potentials. Class I antiarrhythmic drugs can be classified according to their kinetic binding, with drugs exhibiting different effects and exhibiting fast, intermediate, and slow kinetic binding.51<\/sup><\/p>\n

Considering the evaluation of the findings from our research, it can be concluded that the antiarrhythmic effect of the alkaloid F-25 on the aconitine (1 \u03bcM)-induced arrhythmia model in rat papillary muscle is due to its interaction with voltage-gated Na+<\/sup> channels in cardiomyocytes and modification of the transport of Na+<\/sup> and Ca2+<\/sup> ions (Figure 6).<\/p>\n\n\n\n
\"\"<\/td>\nFigure <\/strong>6: <\/strong>Antiarrhythmic effect of<\/strong> the<\/strong> isoquinoline<\/strong> alkaloid<\/strong> F<\/strong>-25<\/strong>\u00a0<\/strong><\/p>\n

Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Acknowledgment<\/strong><\/p>\n

This work was supported by the Science and Technology Development Coordination Committee.<\/p>\n

Funding source<\/strong><\/p>\n

This work was supported by the Ministry of Higher Education, Science and Innovation of Uzbekistan (grant AL-9224104346).<\/p>\n

Conflict of Interest<\/strong><\/p>\n

The author(s) do not have any conflict of interest.<\/p>\n

Data Availability Statement<\/strong><\/p>\n

This statement does not apply to this article.<\/p>\n

Ethics Statement<\/strong><\/p>\n

The experimental protocols complied with the standards and requirements for the humane treatment of animals and the provisions of the Ethical Commission of the IBB at the National University of Uzbekistan. (Protocol No. 7 BEC\/IBB-NUU of 04\/07\/2022) on the use of laboratory animals. Preparations of isolated aortic segments were obtained using a known method.<\/p>\n

Informed Consent Statement<\/strong><\/p>\n

This study did not involve human participants, and therefore, informed consent was not required<\/p>\n

Clinical Trial Registration<\/strong><\/p>\n

This research does not involve any clinical trials<\/p>\n

Permission to reproduce material from other sources<\/strong><\/p>\n

Not Applicable<\/p>\n

Authors\u2019 Contribution<\/strong><\/p>\n